title: Fields of aberrant CpG island hypermethylation in Barrett's esophagus and associated adenocarcinoma.
abstract: Esophageal adenocarcinoma (EAC) is thought to develop through a multistage process in which Barrett's metaplasia progresses through low- and high-grade dysplasia to invasive cancer. Transcriptional silencing of tumor suppressor genes by promoter CpG island hypermethylation has been observed in many types of human cancer. Analysis of CpG island hypermethylation in EAC has thus far been limited to the CDKN2A (p16) gene. In this study, we extend the methylation analysis of EAC to include three other genes, APC, CDH1 (E-cadherin), and ESR1 (ER, estrogen receptor alpha), in addition to CDKN2A. Molecular analysis can provide insight into the complex relationships between tissues with different histologies in Barrett's esophagus and associated adenocarcinoma. Therefore, we have mapped the spatial distribution of methylation patterns in six esophagectomy cases in detail. Hypermethylation of the four CpG islands was analyzed by the MethyLight technique in 107 biopsies derived from these six patients for a total of 428 methylation analyses. Our results show that normal esophageal squamous epithelium is unmethylated at all four CpG islands. CDH1 is unmethylated in most other tissue types as well. Hypermethylation of ESR1 is seen at high frequency in inflammatory reflux esophagitis and at all subsequent stages, whereas APC and CDKN2A hypermethylation is found in Barrett's metaplasia, dysplasia, and EAC. When it occurs, hypermethylation of APC, CDKN2A, and ESR1 is usually found in a large contiguous field, suggesting either a concerted methylation change associated with metaplasia or a clonal expansion of cells with abnormal hypermethylation.
authors.affiliation: Department of Surgery, University of Southern California, Keck School of Medicine, Norris Comprehensive Cancer Center, Los Angeles 90089- 9176, USA.
authors.forename: C A
authors.initials: CA
authors.lastname: Eads
authors.forename: R V
authors.initials: RV
authors.lastname: Lord
authors.forename: S K
authors.initials: SK
authors.lastname: Kurumboor
authors.forename: K
authors.initials: K
authors.lastname: Wickramasinghe
authors.forename: M L
authors.initials: ML
authors.lastname: Skinner
authors.forename: T I
authors.initials: TI
authors.lastname: Long
authors.forename: J H
authors.initials: JH
authors.lastname: Peters
authors.forename: T R
authors.initials: TR
authors.lastname: DeMeester
authors.forename: K D
authors.initials: KD
authors.lastname: Danenberg
authors.forename: P V
authors.initials: PV
authors.lastname: Danenberg
authors.forename: P W
authors.initials: PW
authors.lastname: Laird
authors.forename: K A
authors.initials: KA
authors.lastname: Skinner
mesh_terms: D000230:Adenocarcinoma / Q000235:genetics* / Q000378:metabolism / Q000473:pathology; D000368:Aged; D000369:Aged, 80 and over; D001471:Barrett Esophagus / Q000235:genetics* / Q000378:metabolism / Q000473:pathology; D001706:Biopsy; D015820:Cadherins / Q000235:genetics; D018899:CpG Islands / Q000235:genetics*; D004247:DNA / Q000235:genetics / Q000378:metabolism; D019175:DNA Methylation; D004273:DNA, Neoplasm / Q000235:genetics / Q000378:metabolism; D004938:Esophageal Neoplasms / Q000235:genetics* / Q000378:metabolism / Q000473:pathology; D047628:Estrogen Receptor alpha; D005260:Female; D017491:Genes, APC / Q000235:genetics; D019942:Genes, p16 / Q000235:genetics; D006801:Humans; D008297:Male; D008875:Middle Aged; D011960:Receptors, Estrogen / Q000235:genetics
chemical_list: D015820:Cadherins; D004273:DNA, Neoplasm; D047628:Estrogen Receptor alpha; D011960:Receptors, Estrogen; D004247:DNA